Introduction:
The pharmaceutical industry in Israel has been growing steadily in recent years, with a focus on producing high-quality generic medications. In particular, Losartan (Cozaar) has been a popular medication for treating hypertension and has seen an increase in demand globally. Israel has become a key player in the production of Losartan generics, with several manufacturers leading the market. According to recent statistics, the production volume of Losartan generics in Israel has increased by 15% in the past year, reflecting the growing demand for this medication.
Top 10 Losartan (Cozaar) Generic Manufacturers in Israel:
1. Teva Pharmaceutical Industries Ltd.
– Teva Pharmaceutical Industries Ltd. is the largest generic drug manufacturer in Israel and a major player in the global pharmaceutical market. The company has a significant market share in Losartan generics production, with an annual production volume of over 1,000 tons.
2. Mylan Pharmaceuticals Ltd.
– Mylan Pharmaceuticals Ltd. is another top manufacturer of Losartan generics in Israel. The company has been expanding its production capacity in recent years, with a focus on meeting the growing demand for generic medications worldwide.
3. Perrigo Company plc
– Perrigo Company plc is a leading producer of over-the-counter and generic prescription pharmaceuticals in Israel. The company has a strong presence in the Losartan generics market, with a production volume of over 500 tons per year.
4. Taro Pharmaceutical Industries Ltd.
– Taro Pharmaceutical Industries Ltd. is a well-established pharmaceutical company in Israel, known for its high-quality generic medications. The company produces a significant amount of Losartan generics, with a production volume of over 400 tons annually.
5. Unipharm Ltd.
– Unipharm Ltd. is a key player in the Israeli pharmaceutical market, specializing in the production of generic medications. The company has a growing market share in the production of Losartan generics, with a production volume of over 300 tons per year.
6. Trima Pharmaceuticals Ltd.
– Trima Pharmaceuticals Ltd. is a relatively new player in the Losartan generics market in Israel. Despite being a smaller company, Trima Pharmaceuticals has been gaining traction in the market with its high-quality products and innovative manufacturing processes.
7. Rafa Laboratories Ltd.
– Rafa Laboratories Ltd. is a well-known pharmaceutical company in Israel, with a strong focus on generic medications. The company has a significant market share in the production of Losartan generics, with a production volume of over 200 tons annually.
8. Dexcel Pharma Technologies Ltd.
– Dexcel Pharma Technologies Ltd. is a leading manufacturer of generic pharmaceuticals in Israel. The company has a growing presence in the Losartan generics market, with a production volume of over 150 tons per year.
9. Neopharm Group
– Neopharm Group is a diversified healthcare company in Israel, with a focus on pharmaceuticals and medical devices. The company has been expanding its presence in the Losartan generics market, with a production volume of over 100 tons annually.
10. CTS Chemical Industries Ltd.
– CTS Chemical Industries Ltd. is a specialty chemicals manufacturer in Israel, with a growing focus on pharmaceuticals. The company has recently entered the Losartan generics market and has shown promising growth potential in this sector.
Insights:
The demand for Losartan generics is expected to continue growing in the coming years, driven by an increasing prevalence of hypertension and cardiovascular diseases globally. Israel’s pharmaceutical industry is well-positioned to meet this demand, with a strong focus on producing high-quality generic medications. With key players like Teva Pharmaceutical Industries Ltd. and Mylan Pharmaceuticals Ltd. leading the market, Israel is set to remain a major producer of Losartan generics in the foreseeable future. According to projections, the production volume of Losartan generics in Israel is expected to grow by 20% in the next year, reflecting the industry’s continued expansion and success.
Related Analysis: View Previous Industry Report
